4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. decreased its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 55.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 296,199 shares of the company’s stock after selling 367,458 shares during the period. Assenagon Asset Management S.A. owned approximately 0.52% of 4D Molecular Therapeutics worth $2,221,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Dynamic Technology Lab Private Ltd purchased a new stake in 4D Molecular Therapeutics during the 1st quarter valued at about $39,000. Wexford Capital LP purchased a new position in shares of 4D Molecular Therapeutics in the third quarter worth about $41,000. Quadrature Capital Ltd acquired a new stake in shares of 4D Molecular Therapeutics during the second quarter worth about $42,000. Farther Finance Advisors LLC lifted its holdings in shares of 4D Molecular Therapeutics by 117.4% during the third quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock worth $43,000 after purchasing an additional 2,674 shares during the period. Finally, AQR Capital Management LLC purchased a new stake in 4D Molecular Therapeutics in the first quarter valued at approximately $46,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Stock Performance

Shares of 4D Molecular Therapeutics stock opened at $8.57 on Tuesday. The firm has a 50-day simple moving average of $8.95 and a two-hundred day simple moving average of $9.24. The company has a market cap of $437.50 million, a P/E ratio of -3.54 and a beta of 2.99. 4D Molecular Therapeutics, Inc. has a fifty-two week low of $2.23 and a fifty-two week high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its earnings results on Wednesday, March 18th. The company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.96. 4D Molecular Therapeutics had a negative return on equity of 31.75% and a negative net margin of 164.43%.The firm had revenue of $85.09 million for the quarter, compared to analysts’ expectations of $30.86 million. Equities research analysts forecast that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on FDMT. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Wednesday, January 21st. Royal Bank Of Canada lifted their price objective on shares of 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a research note on Thursday, March 19th. Wall Street Zen raised shares of 4D Molecular Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Friday, March 20th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $21.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a report on Monday. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.25.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.